

Table S1. The correlation between antimicrobial resistance and biofilm formation among MRSA and MSSA isolates

Antibiotics		MRSA				MSSA			
		Biofilm formation (Microtitre plate)				Biofilm formation (Microtitre plate)			
		Non	1+	2+	3+	Non	1+	2+	3+
Penicillin	Resistant	9	33	9	4	64	60	10	3
	Susceptible	0	0	0	0	1	2	2	0
STX	Resistant	3	9	1	3	2	0	0	0
	Susceptible	6	24	8	1	63	62	12	3
Ciprofloxacin	Resistant	8	14	7	4	21	22	9	1
	Susceptible	1	19	2	0	44	40	3	2
Chloramphenicol	Resistant	3	19	2	1	16	29	6	3
	Susceptible	6	14	7	3	49	33	6	0
Minocycline	Resistant	0	0	2	0	0	3	0	0
	Susceptible	9	33	7	4	65	59	12	3
Gentamycin	Resistant	0	1	5	3	1	10	3	2
	Susceptible	9	32	4	1	64	52	9	1
Kanamycin	Resistant	0	1	5	3	1	10	3	1
	Susceptible	9	32	4	1	64	52	9	2
Erythromycin	Resistant	6	19	7	4	20	28	6	2
	Susceptible	3	14	2	0	45	34	6	1
Rifampin	Resistant	0	1	3	1	1	6	1	1
	Susceptible	9	32	6	3	64	56	11	2

STX: Trimethoprim/sulfamethoxazole; MRSA: Methicillin-resistant *Staphylococcus aureus*; MSSA: Methicillin-susceptible *Staphylococcus aureus*

Table S2. Biofilm formation and antibiotics resistance in MRSA and MSSA isolate

Antibiotics		MRSA [†] (n=55)					MSSA [‡] (n=142)				
		Biofilm formation					Biofilm formation				
		Total	Non (n=24)	Weak (n=24)	Moderate (n=6)	Strong (n=4)	Total	Non (n=70)	Weak (n=58)	Moderate (n=11)	Strong (n=3)
		N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Penicillin	Resistance	55 1(100)	24 (43.6)	21 (38.2)	6 (10.9)	4 (7.3)	137 (96.5)	69 (48.6)	56 (39.4)	9 (6.3)	3 (2.1)
	Susceptible	0 (0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5 (3.5)	1 (.7)	2 (1.4)	2 (1.4)	0 (0.0)
Cotrimoxazole	Resistance	16 (29.1)	5 (9.1)	7(12.7)	1 (1.8)	3 (5.5)	2 (1.4)	2 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)
	Susceptible	39 (70.9)	19 (34.5)	14(25.5)	5 (9.1)	1 (1.8)	140 (98.6)	68 (47.9)	58 (40.8)	11 (7.7)	3 (2.1)
Clindamycin	Resistance	32 (58.2))	10 (18.2)	14 (25.5)	4 (7.3)	4 (7.3)	50 (35.2)	19 (13.4)	25 (17.6)	4 (2.8)	2 (1.4)
	susceptible	23 (41.8)	14 (25.5)	7 (12.7)	2 (3.6)	0 (0.0)	92 (64.8)	51 (35.9)	33 (23.2)	7 (4.9)	1 (.7)
Erythromycin	Resistance	36 (65.5)	11 (20.0)	16 (29.1)	5 (9.1)	4 (7.3)	56 (39.4)	21 (14.8)	27 (19.0)	6 (4.2)	2 (1.4)
	susceptible	19 (34.5)	13 (23.6)	5 (9.1)	1 (1.8)	0 (0.0)	86 (60.6)	49 (34.5)	31 (21.8)	5 (3.5)	1 (.7)
Ciprofloxacin	Resistance	33 (60)	12 (21.8)	11 (20.0)	6 (10.9)	4 (7.3)	53 (37.3)	22 (15.5)	21 (14.8)	9 (6.3)	1 (.7)
	susceptible	22 (40)	12 (21.8)	10 (18.2)	0 (0.0)	0 (0.0)	89 (62)	48 (33.8)	37 (26.1)	2 (1.4)	2 (1.4)
Chloramphenicol	Resistance	25 (45.5)	9 (16.4)	13(23.6)	2 (3.6)	1 (1.8)	54 (38)	17 (12.0)	28 (19.7)	6 (4.2)	3 (2.1)
	susceptible	30 (54.5)	15 (27.3)	8 (14.5)	4 (7.3)	3 (5.5)	88 (62)	53 (37.3)	30 (21.1)	5 (3.5)	0 (0.0)
Minocycline	Resistance	2 (3.6)	0 (0.0)	0 (0.0)	2 (3.6)	0 (0.0)	3 (2.1)	0 (0.0)	3 (2.1)	0 (0.0)	0 (0.0)
	susceptible	53 (96.4)	24 (43.6)	21 (38.2)	4 (7.3)	4 (7.3)	139 (97.9)	70 (49.3)	55 (38.7)	11 (7.7)	3 (2.1)
Rifampicin	Resistance	5 (9.1)	0 (0.0)	1 (1.8)	3 (5.5)	1 (1.8)	9 (6.3)	1 (.7)	6 (4.2)	1 (.7)	1 (.7)
	susceptible	50 (90.9)	24 (43.6)	20 (36.4)	3 (5.5)	3 (5.5)	133 (93.7)	69 (48.6)	52 (36.6)	10 (7.0)	2 (1.4)
Kanamycin	Resistance	9 (16.4)	0 (0.0)	1 (1.8)	5 (9.1)	3 (5.5)	15 (10.6)	1 (.7)	10 (7.0)	3 (2.1)	1 (.7)
	susceptible	46 (83.6)	24 (43.6)	20 (36.4)	1 (1.8)	1 (1.8)	127 (89.4)	69 (48.6)	48 (33.8)	8 (5.6)	2 (1.4)
Gentamycin	Resistance	9 (16.4)	0 (0.0)	1 (1.8)	5 (9.1)	3 (5.5)	16 (11.3)	1 (.7)	10 (7.0)	3 (2.1)	2 (1.4)
	susceptible	46 (83.6)	24 (43.6)	20 (36.4)	1 (1.8)	1 (1.8)	126 (88.7)	69 (48.6)	48 (33.8)	8 (5.6)	1 (.7)

MRSA: Methicillin-resistant *Staphylococcus aureus*; MSSA: Methicillin-susceptible *Staphylococcus aureus*

Table S3. The genes accession numbers

Gene	Accession number
<i>Nuc</i>	MF581003
<i>Mec</i>	MF662104
<i>clfA</i>	MF662106
<i>clfB</i>	MG813894
<i>finA</i>	MG820748
<i>finB</i>	MG833032
<i>icaA</i>	MF382008
<i>icaB</i>	MF630927
<i>icaC</i>	MF581002
<i>icaD</i>	MF662105
<i>Hlg</i>	MF276896
<i>Pvl</i>	MF187966